Gilead Sciences (GILD) PT Set at $80.00 by Credit Suisse Group

Gilead Sciences (NASDAQ:GILD) received a $80.00 target price from equities research analysts at Credit Suisse Group in a note issued to investors on Tuesday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target would indicate a potential upside of 5.71% from the company’s current price.

A number of other equities research analysts have also commented on the stock. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, April 11th. Barclays reissued an “overweight” rating and set a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a report on Tuesday, March 6th. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Royal Bank of Canada reissued a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a report on Friday, February 23rd. Finally, Leerink Swann reissued a “market perform” rating and set a $80.00 price objective (down previously from $83.00) on shares of Gilead Sciences in a report on Thursday, February 22nd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $88.61.

How to Become a New Pot Stock Millionaire

Shares of Gilead Sciences stock opened at $75.68 on Tuesday. The stock has a market cap of $97,384.55, a P/E ratio of 8.84, a PEG ratio of -1.72 and a beta of 1.19. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same quarter last year, the company posted $2.70 EPS. equities research analysts forecast that Gilead Sciences will post 6.21 EPS for the current fiscal year.

In related news, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the transaction, the chief financial officer now owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.51, for a total transaction of $2,087,750.00. Following the transaction, the executive vice president now directly owns 62,738 shares in the company, valued at approximately $5,239,250.38. The disclosure for this sale can be found here. Insiders have sold a total of 308,600 shares of company stock worth $24,328,226 in the last three months. 1.16% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in GILD. Rowland & Co. Investment Counsel ADV acquired a new stake in Gilead Sciences during the 2nd quarter worth approximately $153,000. Stonebridge Capital Advisors LLC raised its holdings in Gilead Sciences by 260.6% during the 2nd quarter. Stonebridge Capital Advisors LLC now owns 73,943 shares of the biopharmaceutical company’s stock worth $5,234,000 after buying an additional 53,440 shares during the period. Scotia Capital Inc. raised its holdings in Gilead Sciences by 9.8% during the 2nd quarter. Scotia Capital Inc. now owns 146,411 shares of the biopharmaceutical company’s stock worth $10,362,000 after buying an additional 13,078 shares during the period. Linscomb & Williams Inc. raised its holdings in Gilead Sciences by 10.1% during the 2nd quarter. Linscomb & Williams Inc. now owns 5,806 shares of the biopharmaceutical company’s stock worth $411,000 after buying an additional 531 shares during the period. Finally, Chiron Investment Management LLC raised its holdings in Gilead Sciences by 42.9% during the 2nd quarter. Chiron Investment Management LLC now owns 266,500 shares of the biopharmaceutical company’s stock worth $18,863,000 after buying an additional 80,000 shares during the period. 78.35% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This article was published by Week Herald and is the property of of Week Herald. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://weekherald.com/2018/04/19/gilead-sciences-gild-pt-set-at-80-00-by-credit-suisse-group.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply